
Ask a doctor about a prescription for BRIVIACT 10 mg/ml INJECTABLE SOLUTION AND PERFUSION SOLUTION
Package Leaflet: Information for the Patient
Briviact 10 mg/ml Solution for Injection and Infusion
brivaracetam
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Keep this leaflet. You may need to read it again.
Contents of the pack
What is Briviact
Briviact contains the active substance brivaracetam. It belongs to a group of medicines called “antiepileptics”. These medicines are used to treat epilepsy.
What is Briviact used for
Do not use Briviact
Warnings and precautions
Talk to your doctor or pharmacist before starting Briviact:
Children
Do not give Briviact to children under 2 years of age.
Using Briviact with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
In particular, tell your doctor if you are taking any of the following medicines, as your doctor may need to adjust your dose of Briviact:
Using Briviact with alcohol
It is not recommended to use this medicine with alcohol.
Pregnancy and breastfeeding
Women of childbearing age should discuss the use of contraceptives with their doctor.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
It is not recommended to use Briviact if you are pregnant or breastfeeding, as the effects of Briviact on pregnancy and the fetus are unknown.
It is not recommended to breastfeed while taking Briviact, as Briviact is excreted in breast milk.
Do not stop treatment without consulting your doctor first. Stopping treatment may increase the number of seizures you have and harm your baby.
Driving and using machines
Briviact contains sodium
This medicine contains 19.1 mg of sodium (the main component of table/cooking salt) per vial. This is equivalent to 1% of the maximum recommended daily sodium intake for an adult.
Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, consult your doctor or pharmacist again.
You will use Briviact together with other medicines to treat epilepsy.
Dose
Your doctor will calculate the correct daily dose for you. Take the daily dose in two equal doses, with an interval of approximately 12 hours.
Adolescents and children weighing 50 kg or more, and adults
Adolescents and children weighing from 20 kg to less than 50 kg
Children weighing from 10 kg to less than 20 kg
Patient with liver problems
If you have liver problems:
How to use Briviact
Briviact is administered by a doctor or nurse as an injection or infusion. This medicine is injected slowly into your vein or administered as an infusion (drip) over 15 minutes.
Duration of treatment with Briviact
If you use more Briviact than you should
If you think you have been given too much Briviact, consult your doctor immediately.
If you stop treatment with Briviact
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common:may affect more than 1 in 10 people.
Common:may affect up to 1 in 10 people.
Uncommon:may affect up to 1 in 100 people
Other side effects in children
Common:may affect up to 1 in 10 people
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Composition of Briviact
The active substance is brivaracetam.
The other ingredients are: sodium acetate (trihydrate), glacial acetic acid, sodium chloride, water for injections.
Appearance of the product and pack size
Briviact 10 mg/ml solution for injection and infusion is a clear, colorless, and sterile solution.
Briviact 10 mg/ml solution for injection and infusion, 5 ml vial is packaged in a cardboard box with 10 vials.
Marketing authorisation holder and manufacturer
Marketing authorisation holder
UCB Pharma, S.A., Allée de la Recherche 60, B-1070, Brussels, Belgium.
Manufacturer
UCB Pharma, S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium.
You can request more information about this medicine from the local representative of the marketing authorisation holder:
Belgium UCB Pharma SA/NV Tel: + 32 / (0)2 559 92 00 | Lithuania UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Finland) |
Bulgaria ??????? ????????? ??? Tel: + 359 (0) 2 962 30 49 | Luxembourg UCB Pharma SA/NV Tel: + 32 / (0)2 559 92 00 (Belgium) |
Czech Republic UCB s.r.o. Tel: + 420 221 773 411 | Hungary UCB Magyarország Kft. Tel: + 36-(1) 391 0060 |
Denmark UCB Nordic A/S Tel: + 45 / 32 46 24 00 | Malta Pharmasud Ltd. Tel: + 356 / 21 37 64 36 |
Germany UCB Pharma GmbH Tel: + 49 / (0)2173 48 4848 | Netherlands UCB Pharma B.V. Tel: + 31 / (0)76-573 11 40 |
Estonia UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Finland) | Norway UCB Nordic A/S Tel: + 47 / 67 16 5880 |
Greece UCB ??? Tel: + 30 / 2109974000 | Austria UCB Pharma GmbH Tel: + 43-(0)1 291 80 00 |
Spain UCB Pharma, S.A. Tel: + 34 / 91 570 34 44 | Poland UCB Pharma Sp. z o.o. / VEDIM Sp. z o.o. Tel: + 48 22 696 99 20 |
France UCB Pharma S.A. Tel: + 33 / (0)1 47 29 44 35 | Portugal UCB Pharma (Produtos Farmacêuticos), Lda Tel: + 351 / 21 302 5300 |
Croatia Medis Adria d.o.o. Tel: +385 (0) 1 230 34 46 | Romania UCB Pharma Romania S.R.L. Tel: + 40 21 300 29 04 |
Ireland UCB (Pharma) Ireland Ltd. Tel: + 353 / (0)1-46 37 395 | Slovenia Medis, d.o.o. Tel: + 386 1 589 69 00 |
Iceland Vistor hf. Tel: + 354 535 7000 | Slovakia UCB s.r.o., organizačná zložka Tel: + 421 (0) 2 5920 2020 |
Italy UCB Pharma S.p.A. Tel: + 39 / 02 300 791 | Finland UCB Pharma Oy Finland Tel: + 358 9 2514 4221 |
Cyprus Lifepharma (Z.A.M.) Ltd Tel: + 357 22 05 63 00 | Sweden UCB Nordic A/S Tel: + 46 / (0) 40 29 49 00 |
Latvia UCB Pharma OÜ Tel: + 358 9 2514 4221 (Finland) | United Kingdom UCB (Pharma) Ireland Ltd. Tel: + 353 / (0)1-46 37 395 |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
This information is intended only for healthcare professionals:
Briviact solution for injection and infusion can be administered as an intravenous bolus or as an intravenous infusion:
Briviact can be diluted with the following solutions: sodium chloride 9 mg/ml (0.9%), glucose solution for injection 50 mg/ml (5%), or Ringer's lactate solution.
Each vial of Briviact solution for injection and infusion is for single use only. The unused solution should be discarded (see section 3).
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for BRIVIACT 10 mg/ml INJECTABLE SOLUTION AND PERFUSION SOLUTION – subject to medical assessment and local rules.